肝细胞癌
医学
索拉非尼
肝癌
放射科
内科学
米兰标准
肿瘤科
肝硬化
癌
作者
Seyda Gunduz,Gia Saini,Nicole Segaran,Sailen G. Naidu,Indravadan Patel,Sadeer Alzubaidi,Rahmi Oklu
出处
期刊:Digestive disease interventions
[Georg Thieme Verlag KG]
日期:2021-09-01
卷期号:05 (03): 268-276
标识
DOI:10.1055/s-0041-1732304
摘要
Hepatocellular carcinoma (HCC) is the fastest-growing cancer worldwide, causing significant morbidity and mortality. Surgical resection, ablation, or transplantation is the best treatment option for patients with HCC. However, only about one-fifth of patients are suitable for such primary curative treatments due to underlying liver disease or rapid extension of the tumor. Image-guided locoregional therapies may prove an important alternative in this scenario, particularly transarterial radioembolization (TARE) with yttrium-90 (Y-90). Based on many studies, TARE can be considered a curative treatment option for patients with early-stage HCC, a bridge to transplantation, and a method for downstaging tumors to give patients with unresectable HCC a chance to potentially receive a curative treatment. TARE can be also combined with other treatment modalities to provide a better quality of life in patients when compared with systemic therapy in patients with unresectable HCC. Here, we discuss the use of TARE in the approach to HCC patients who are in early, intermediate, or advanced stages.
科研通智能强力驱动
Strongly Powered by AbleSci AI